| CITATION: | Pharmacy Board of Australia v Heron [2011] QCAT 424 |
| PARTIES: | Pharmacy Board of Australia (Applicant) |
| v | |
| Edmund Heron (Respondent) |
| APPLICATION NUMBER: | OCR273-10 |
| MATTER TYPE: | Occupational regulation matters |
| HEARING DATE: | On the papers |
| HEARD AT: | Brisbane |
| DECISION OF: | Judge Fleur Kingham, Deputy President Assisted by: Ms K Allen Ms P Mathers Mr K Walsh |
| DELIVERED ON: | 9 September 2011 |
| DELIVERED AT: | Brisbane |
| ORDERS MADE: | 1. Mr Heron’s registration is suspended for three months from the date of these orders. That suspension is wholly suspended for 12 months provided Mr Heron does not face further disciplinary action and complies with the orders that follow. 2. Mr Heron must complete a course in ethical decision making approved by the Board within 6 months and must submit documentary evidence of completion to the Board. 3. Upon Mr Heron’s endorsement for Pseudoephedrine (PSE) being reinstated by the Chief Executive, Queensland Health Mr Heron must participate in a 12 month mentoring program with a mentor he nominates and who is approved by the Board. The mentoring program should focus upon ethical decision making in dispensing, in particular the need to counsel clients on the therapeutic use of PSE and the alternatives which are available and can be substituted safely.4. |
| CATCHWORDS: | DISCIPLINARY – Pharmacist – Where pharmacist employed part time in a pharmacy targeted by drug runners for illicit manufacture of methamphetamine – where pharmacist dispensed when he could not reasonably be satisfied there was a therapeutic need for products containing pseudoephedrine and despite notations on Project STOP – where pharmacist co-operated in proceedings and genuinely insightful and remorseful – whether orders jointly proposed by the parties were appropriate Health (Drugs and Poisons) Regulation 1996, ss 277, 285A Health Practitioners (Professional Standards) Act 1999, ss 124(1)(a), 405L, 405P(1), (5) Health Practitioner National Law (Qld), s 289 Pharmacists Board of Queensland v Coffey [2008] QHPT Griffin SC DCJ 14/10/08 cited Pharmacists Board of Queensland v Mikhail [2010] QCAT 621 cited |
APPEARANCES and REPRESENTATION (if any):
This matter was heard and determined on the papers in accordance with section 32 of the Queensland Civil and Administrative Act 2009.
REASONS FOR DECISION
These proceedings involve pseudoephedrine (PSE), a drug prone to abuse. It is the main precursor chemical in the manufacture of methamphetamine, commonly referred to as speed. In recent years, health regulators and the profession have pursued a national strategy to restrict illegitimate access to products containing PSE, in order to deal with the growing incidence of illicit drug manufacture.[1]
[1]National Strategy to Prevent the Diversion of Precursor Chemicals into Illicit Drug Manufacture (National Precursor Strategy). See conduct
Mr Heron, a pharmacist for almost 30 years, concedes he has engaged in unsatisfactory professional conduct in the way in which he dispensed medications involving PSE to certain customers between 1 January 2008 and 26 November 2009 (the sales period).
The primary professional concern of a pharmacist must be for the health and wellbeing of consumers and the community. The Pharmacists Code of Conduct requires a pharmacist to…
Keep reading for free
Create a free CaseChat account to read Pharmacy Board of Australia v Heron and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2011] QCAT 424
- Decision Date
CaseChat Overview and Summary
The primary legal issue before the Tribunal was whether Mr Heron's actions warranted disciplinary action, and if so, what form that action should take. The Tribunal needed to consider the gravity of Mr Heron's breaches, his level of insight and remorse, and the effectiveness of the proposed orders in preventing future misconduct. The case also involved assessing the appropriateness of jointly proposed orders by the Board and Mr Heron, which included a suspension of registration and mandatory training and mentoring.
Dr R C J Smith found that Mr Heron's actions were indeed deserving of disciplinary action, given the circumstances under which he dispensed the pseudoephedrine products. However, the Tribunal also noted Mr Heron's genuine insight, remorse, and co-operation in the proceedings. Considering these factors, the Tribunal concluded that the jointly proposed orders were appropriate. These orders included a three-month suspension of Mr Heron's registration, contingent on his compliance with additional conditions over a 12-month period. The conditions mandated completion of an ethical decision-making course and participation in a 12-month mentoring program focusing on ethical dispensing practices.
The Tribunal's orders were designed to address Mr Heron's past failings while also providing him with the tools and support necessary to prevent future misconduct. The Tribunal's decision balanced the need for deterrence and public protection with the opportunity for rehabilitation and reintegration into the profession.
Orders
Orders of the court
1. Mr Heron’s registration is suspended for three months from the date of these orders. That suspension is wholly suspended for 12 months provided Mr Heron does not face further disciplinary action and complies with the orders that follow.
2. Mr Heron must complete a course in ethical decision making approved by the Board within 6 months and must submit documentary evidence of completion to the Board.
3. Upon Mr Heron’s endorsement for Pseudoephedrine (PSE) being reinstated by the Chief Executive, Queensland Health Mr Heron must participate in a 12 month mentoring program with a mentor he nominates and who is approved by the Board.
The mentoring program should focus upon ethical decision making in dispensing, in particular the need to counsel clients on the therapeutic use of PSE and the alternatives which are available and can be substituted safely.4.